JBJean-Baptiste Beauval

Jean-Baptiste Beauval

*This is an algorithmically generated author record based on publicly available information.

Jean-Baptiste Beauval has a total of 375 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    VISUCHIR 2024 Ecological Benchmarking of French Private Centers Using a Perioperative Digital Therapeutic: A Descriptive Early-Adopter Comparison (Preprint)

    by Bogdan Adrian Buhas, Eric Potiron, Truong An Nguyen, Benjamin Pradère, Justine Figurelli, Christophe Almeras, Jean-Baptiste Beauval, Gilles Pasticier, Fabien Vidal, Guillaume Ploussard

    Using publicly available 2024 VISUCHIR (Visualisation de la Chirurgie) benchmarking indicators, we performed a descriptive ecological comparison of national private-sector values and 4 early-adopter French private departments implementing the Betty Coaching perioperative digital pathway; early-adopter departments showed a directionally favorable, unadjusted profile for same-day discharge, mean length of stay, and VISUCHIR-reported readmission-evolution indicators, without causal inference.


  • Open Access

    The Impact of a Digital Health Pathway on Complications Following HIFU Treatment in Prostate Cancer Patients—A Pre- and Postintervention Study

    by Olga Katzendorn, Alessandro Uleri, Michael Baboudjian, Jean-Baptiste Beauval, Harry Toledano, Vincent Bailly, Guillaume Ploussard, Christophe Tollon

    Background/Objectives: Digital health pathways, including prehabilitation programs, may help reduce complications after urologic procedures. This study assesses the impact of a digital health intervention on infectious complications, urinary retention, and unplanned patient contacts after high-intensity focused ultrasound (HIFU) treatment for prostate cancer. Methods: A pre-/post-intervention study design was applied. The intervention consisted of implementing a mobile health pathway via a mobile application integrated into the perioperative management of patients undergoing HIFU treatment for prostate cancer. Urinary complication rates and unplanned patient contacts with the surgical team before and after implementation were compared using the Mann–Whitney U test. Results: 58 patients were included in the analysis. Demographic, tumor, and treatment characteristics were comparable between both groups. The post-intervention group showed a lower incidence of symptomatic urinary infections (3 vs. 10; p = 0.019) and fewer unplanned visits (4 vs. 10; p = 0.047) after the implementation of the mobile application. No significant differences in rates of acute urinary retention and unplanned communication with the surgical team were observed. Conclusions: Integration of a digital health pathway was associated with reduced infectious complications and fewer unplanned visits after HIFU treatment. Incorporating such tools into perioperative management may improve patient outcomes.


  • Open Access

    Personalized Mobile App–Based Program for Preparation and Recovery After Radical Prostatectomy: Initial Evidence for Improved Outcomes From a Prospective Nonrandomized Study

    by Alberto Martini, Claudia Kesch, Alae Touzani, Giorgio Calleris, Bogdan Buhas, Rawad Abou-Zahr, Razvan-George Rahota, Benjamin Pradère, Christophe Tollon, Jean-Baptiste Beauval, et al.

    Background: eHealth can help replicate the benefits of conventional surgical prehabilitation programs and overcome organizational constraints related to human resources and health care–related costs. Objective: We aimed to assess the impact of an optimized perioperative program using a personalized mobile app designed for preparation and recovery after radical prostatectomy (RP). Methods: We report on a series of 122 consecutive robot-assisted RP before and after the implementation of the betty.care app (cohort A: standard of care, n=60; cohort B: optimized program, n=62). The primary end point was continence recovery, defined as “0 or 1 safety pad per day” at 6 weeks after surgery. Secondary end points were length of stay, same-day discharge, complications, readmissions, and number of days alive and out of hospital within 30 days from surgery. Results: Both cohorts were comparable in terms of age, prostate-specific antigen, prostate volume, and disease aggressiveness. Intraoperative parameters (lymph node dissection, operative time, and bilateral nerve-sparing surgery) were comparable in both groups, except for blood loss, which was significantly higher in cohort B (182 vs 125 cc; P=.008). The 6-week continence rate was improved in cohort B in both univariable and multivariable analyses (92% vs 75%; P=.01). There were trends favoring cohort B for all secondary end points with a minimal 30% benefit compared with cohort A. Grade 2 or more complications occurred less frequently in cohort B (13% vs 3.2%; P=.042). Same-day discharge and readmission rates were 35% and 53% (P=.043), and 3.3% and 1.6% (P=.54) in cohorts A and B, respectively. Mean length of stay was reduced by 0.2 days in cohort B (0.58 vs 0.78 days; P=.10). The main limitation was the absence of randomization. Conclusions: The implementation of a mobile app that provides a holistic approach to the perioperative period, integrating prehabilitation, rehabilitation, and remote monitoring, could lead to the improvement of important functional outcomes after RP and could replicate an on-site prehabilitation program. Multicenter validation is needed.


  • Oncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129

    by Alberto Martini, Jean-Christophe Bernhard, Ugo G. Falagario, Guillaume Herman, Arna Geshkovska, Zine-Eddine Khene, François Audenet, Cecile Champy, Franck Bruyere, Muriel Rolland, et al.

    Article: Oncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129 - Minerva Urology and Nephrology 2024 October;76(5):578-87 - Minerva Medica - Journals


  • Open versus robotic partial nephrectomy in obese patients: a multi-institutional propensity score-matched analysis (UroCCR 43—Robese study)

    by Jean Baptiste Beauval, Zine-Eddine Khene, Mathieu Roumiguié, Razvan Rahota, Arnaud Mejean, Nicolas Doumerc, Morgan Roupret, Philippe Paparel, Arnauld Villers, Franck Bruyere, et al.

    Introduction There is limited evidence on the outcomes of robotic partial nephrectomy (RPN) and open partial nephrectomy (OPN) in obese patients (BMI ≥ 30 kg/m2). In this study, we aimed to compare perioperative and oncological outcomes of RPN and OPN. Methods We relied on data from patients who underwent PN from 2009 to 2017 at 16 departments of urology participating in the UroCCR network, which were collected prospectively. In an effort to adjust for potential confounders, a propensity-score matching was performed. Perioperative outcomes were compared between OPN and RPN patients. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Results Overall, 1277 obese patients (932 robotic and 345 open were included. After propensity score matching, 166 OPN and 166 RPN individuals were considered for the study purposes; no statistically significant difference among baseline demographic or tumor‐specific characteristics was present. A higher overall complication rate and major complications rate were recorded in the OPN group (37 vs. 25%, p = 0.01 and 21 vs. 10%, p = 0.007; respectively). The length of stay was also significantly longer in the OPN group, before and after propensity-score matching (p < 0.001). There were no significant differences in Warm ischemia time (p = 0.66), absolute change in eGFR (p = 0.45) and positive surgical margins (p = 0.12). At a median postoperative follow-up period of 24 (8–40) months, DFS and OS were similar in the two groups (all p > 0.05). Conclusions In this study, RPN was associated with better perioperative outcomes (improvement of major complications rate and LOS) than OPN. The oncological outcomes were found to be similar between the two approaches.


  • Open Access

    Label-Free SERS of Urine Components: A Powerful Tool for Discriminating Renal Cell Carcinoma through Multivariate Analysis and Machine Learning Techniques

    by Bogdan Adrian Buhas, Valentin Toma, Jean-Baptiste Beauval, Iulia Andras, Răzvan Couți, Lucia Ana-Maria Muntean, Radu-Tudor Coman, Teodor Andrei Maghiar, Rareș-Ionuț Știufiuc, Constantin Mihai Lucaciu, et al.

    The advent of Surface-Enhanced Raman Scattering (SERS) has enabled the exploration and detection of small molecules, particularly in biological fluids such as serum, blood plasma, urine, saliva, and tears. SERS has been proposed as a simple diagnostic technique for various diseases, including cancer. Renal cell carcinoma (RCC) ranks as the sixth most commonly diagnosed cancer in men and is often asymptomatic, with detection occurring incidentally. The onset of symptoms typically aligns with advanced disease, aggressive histology, and unfavorable prognosis, and therefore new methods for an early diagnosis are needed. In this study, we investigated the utility of label-free SERS in urine, coupled with two multivariate analysis approaches: Principal Component Analysis combined with Linear Discriminant Analysis (PCA-LDA) and Support Vector Machine (SVM), to discriminate between 50 RCC patients and 44 healthy donors. Employing LDA-PCA, we achieved a discrimination accuracy of 100% using 13 principal components, and an 88% accuracy in discriminating between different RCC stages. The SVM approach yielded a training accuracy of 100%, a validation accuracy of 99% for discriminating between RCC and controls, and an 80% accuracy for discriminating between stages. The comparative analysis of raw and normalized SERS spectral data shows that while raw data disclose relative concentration variations in urine metabolites between the two classes, the normalization of spectral data significantly improves the accuracy of discrimination. Moreover, the selection of principal components with markedly distinct scores between the two classes serves to alleviate overfitting risks and reduces the number of components employed for discrimination. We obtained the accuracy of the discrimination between the RCC patients cases and healthy donors of 90% for three PCs and a linear discrimination function, and a 88% accuracy of discrimination between stages using six PCs, mitigating practically the risk of overfitting and increasing the robustness of our analysis. Our findings underscore the potential of label-free SERS of urine in conjunction with chemometrics for non-invasive and early RCC detection.


  • Open Access

    Personalized Mobile App–Based Program for Preparation and Recovery After Radical Prostatectomy: Initial Evidence for Improved Outcomes From a Prospective Nonrandomized Study (Preprint)

    by Alberto Martini, Claudia Kesch, Alae Touzani, Giorgio Calleris, Bogdan Buhas, Rawad Abou-Zahr, Razvan-George Rahota, Benjamin Pradère, Christophe Tollon, Jean-Baptiste Beauval, et al.

    BACKGROUND eHealth can help replicate the benefits of conventional surgical prehabilitation programs and overcome organizational constraints related to human resources and health care–related costs. OBJECTIVE We aimed to assess the impact of an optimized perioperative program using a personalized mobile app designed for preparation and recovery after radical prostatectomy (RP). METHODS We report on a series of 122 consecutive robot-assisted RP before and after the implementation of the betty.care app (cohort A: standard of care, n=60; cohort B: optimized program, n=62). The primary end point was continence recovery, defined as “0 or 1 safety pad per day” at 6 weeks after surgery. Secondary end points were length of stay, same-day discharge, complications, readmissions, and number of days alive and out of hospital within 30 days from surgery. RESULTS Both cohorts were comparable in terms of age, prostate-specific antigen, prostate volume, and disease aggressiveness. Intraoperative parameters (lymph node dissection, operative time, and bilateral nerve-sparing surgery) were comparable in both groups, except for blood loss, which was significantly higher in cohort B (182 vs 125 cc; P=.008). The 6-week continence rate was improved in cohort B in both univariable and multivariable analyses (92% vs 75%; P=.01). There were trends favoring cohort B for all secondary end points with a minimal 30% benefit compared with cohort A. Grade 2 or more complications occurred less frequently in cohort B (13% vs 3.2%; P=.042). Same-day discharge and readmission rates were 35% and 53% (P=.043), and 3.3% and 1.6% (P=.54) in cohorts A and B, respectively. Mean length of stay was reduced by 0.2 days in cohort B (0.58 vs 0.78 days; P=.10). The main limitation was the absence of randomization. CONCLUSIONS The implementation of a mobile app that provides a holistic approach to the perioperative period, integrating prehabilitation, rehabilitation, and remote monitoring, could lead to the improvement of important functional outcomes after RP and could replicate an on-site prehabilitation program. Multicenter validation is needed.

  • Open Access

    Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU)

    by Amine Saouli, Alain Ruffion, Charles Dariane, Eric Barret, Gaëlle Fiard, Gaelle Fromont Hankard, Gilles Créhange, Guilhem Roubaud, Jean Baptiste Beauval, Laurent Brureau, et al.

    The aim of this study was to systematically review the current evidence regarding the oncological and functional outcomes of salvage radical prostatectomy (sRP) for recurrent prostate cancer. A systematic review was conducted throughout September 2022 using the PubMed, Science Direct, Scopus, and Embase databases. Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were followed to identify eligible studies. A total of 55 studies (3836 patients) met our eligibility criteria. The vast majority of men included had radiation therapy (including brachytherapy) as their first-line treatment (n = 3240, 84%). Other first-line treatments included HIFU (n = 338, 9%), electroporation (n = 59, 2%), proton beam therapy (n = 54, 1.5%), cryotherapy (n = 34, 1%), focal vascular targeted photodynamic therapy (n = 22, 0.6%), and transurethral ultrasound ablation (n = 19, 0.5%). Median preoperative PSA, at the time of recurrence, ranged from 1.5 to 14.4 ng/mL. The surgical approach was open in 2300 (60%) cases, robotic in 1465 (38%) cases, and laparoscopic in 71 (2%) cases. Since 2019, there has been a clear increase in robotic versus conventional surgery (1245 versus 525 cases, respectively). The median operative time and blood loss ranged from 80 to 297 min and 75 to 914 mL, respectively. Concomitant lymph node dissection was performed in 2587 cases (79%). The overall complication rate was 34%, with a majority of Clavien grade I or II complications. Clavien ≥ 3 complications ranged from 0 to 64%. Positive surgical margins were noted in 792 cases (32%). The median follow-up ranged from 4.6 to 94 months. Biochemical recurrence after sRP ranged from 8% to 51.5% at 12 months, from 0% to 66% at 22 months, and from 48% to 59% at 60 months. The specific and overall survival rates ranged from 13.4 to 98% and 62 to 100% at 5 years, respectively. Urinary continence was maintained in 52.1% of cases. sRP demonstrated acceptable oncological outcomes. These results, after sRP, are influenced by several factors, and above all by pre-treatment assessment, including imaging, with the development of mpMRI and metabolic imaging. Our results demonstrated that SRP can be considered a suitable treatment option for selected patients, but the level of evidence remains low.


  • Extension des critères d’inclusion pour la surveillance active dans le cancer de la prostate à risque intermédiaire

    by M. Baboudjian, T. Roumeguere, R. Diamand, J. Roche, J. Beauval, D. Benamran, A. Fourcade, G. Fiard, G. Fromont, M. Roumiguie, et al.

  • Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes

    by Nicolas Branger, Franck Bladou, Gregory Verhoest, Sophie Knipper, Grégoire Robert, Jean-Christophe Bernhard, Jean-Baptiste Beauval, Abderrahmane Khaddad, Anne Mauger De Varennes, Aude Fléchon, et al.

    Purpose To evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT). Methods We retrospectively analyzed patients from four tertiary centers who underwent PC-RARPLND for mGCT, from 2011 to 2021. Previous treatment of mGCT, intraoperative and postoperative complications, and early oncologic outcomes were assessed. Results Overall, 66 patients were included. The majority of patients had non-seminoma mTGCT (89%). Median size of retroperitoneal lymph node (RLN) before surgery was 26 mm. Templates of PC-RARPLND were left modified, right modified, and full bilateral in 56%, 27%, and 14%, respectively. Median estimated blood loss and length of stay were 50 mL [50–150] and 2 [1–3] days. Four patients (6.1%) had a vascular injury, only one with significant blood loss and conversion to open surgery (OS). Two other patients had a conversion to OS for difficulty of dissection. No patient had transfusion, most frequent complications were ileus (10.6%) and symptomatic lymphorrea (7.6%) and no complications grade IIIb or more occurred. With a median follow-up of 16 months, two patients had a relapse, all outside of the surgical template (one in the retrocrural space with reascending markers, one in lungs). Conclusion PC-RARPLND is a challenging surgery. In expert centers and for selected patients, it seemed safe and feasible, with a low morbidity. Further prospective evaluation of this procedure and long-term oncologic results are needed.